Flaskdata.io Launches Software Architecture For Digital Clinical Trials And Healthcare

The Israeli tech company Flaskdata.io released today, a reference software architecture for reducing the time to completion of Phase 2 and Phase 3 clinical trials by 3-6 months.

Fllaskdata.io CEO Danny Lieberman says, "There are a multitude of challenges in clinical research, but the most significant is the delays in the completion of clinical trials. 12-18 month delays of Phase 3 trial completion are delays of therapeutics for people. The 2020 COVID-19 pandemic made time-to-market a life-and-death question for all of us."

Clinicala trial delays are due to variability in data which are in turn caused by variability in procedural adherence and verified data collected by research sites. This is a problem addressed by the Flaskdata.io software architecture for automated detection and response

In particular, Flaskdata.io hopes to give companies that work in the life sciences the information they need to adopt practices and tools that eliminate the uncertainty, human error and inefficient nature that is inherent to manual data processing. Their new software architecture aims to resolve all these problems and more. Download the white paper describing the Flaskdata.io software architecture here - Get a copy of the Flaskdata white paper - A software architecture for speed in clinical trials

The need for speed and efficiency in Phase 2 and 3 clinical trials is the greatest in our generation due to the COVID-19 outbreak. Given the high (and rising) demand for a safe and effective vaccine as well as therapeutic procedures and diagnostic tools, many companies and organizations are pushing their resources to their limits in an attempt to hasten the development of these procedures and medical technologies. However, the fact of the matter is that these companies are likely to be hindered by their reliance on manual data processing, which is prone to human error and takes exorbitantly more time than would be required by a more automated process. Fortunately, Flaskdata.io believes they have the solution these companies are looking for. Their architecture is specifically designed to embody three distinct priorities: to be fast, open and minimalistic.

“The objective of the technical and business architectures,” states Flaskdata.io, “is to deliver interpretable data in an immediate picture to the sponsor, to use technology to automate quality assurance of the data and to enable physicians, study nurses and site coordinators to focus on caring for patients.” Such a goal can be difficult to achieve using more conventional methods, especially given that such methods also lead to issues with data integrity. For instance, the sheer size of a development program for a vaccine may include trials that take place all over the globe, and this is exacerbated if multiple entities with their own individual practices are responsible for providing separate sets of data in a coalition. The answer lies in automating these procedures and providing all involved parties with the real-time access they require to exchange data and move their operations forward at a suitable rate.

No matter how well they try to coordinate themselves, errors are inevitable. The problem here arises when these companies are forced to take additional measures in order to correct these errors—this process takes time. In less stressful periods, a company will simply incur bigger costs the more time a product takes to develop. Today, with COVID-19 forcing economies to a halt and threatening lives around the world, the stakes are far greater.

Notably, a number of life science companies have already tested the capabilities of Flaskdata.io’s platform and found great success in its ability to modernize their operations. As such, it is the company’s hope that other entities in the industry will look at these customer case studies and take the necessary steps to give themselves a similar advantage.

For instance, Elana Markovitz from Orthospace, a Stryker Medical company, explains that, “OrthoSpace develops and commercializes simple-to-implant, biodegradable balloon systems for the orthopaedic market. The company aims to create effective solutions for orthopaedics that reduce pain and increase patients’ range of motion while preserving patient bone and joint structures. The company’s first product has the CE mark and is currently marketed in Europe. InSpace™ is indicated for patients who suffer from rotator cuff injury, reducing shoulder pain and improving range of motion.”

They continue, “FlaskData is a fascinating and novel tool for reinforcing patient adherence. We look forward to seeing FlaskData.io continue to develop and disseminate the technology in the Europe and the US. The ability of a smart mobile agent to increase a patient’s compliance with a clinical protocol can have a significant impact on obtaining statistically-meaningful results in clinical trials and immense importance for medical practice. We are currently working with FlaskData.io in post-marketing studies, monitoring for patient safety and compliance in the UK and the Europe.”

More information can be found on Flaskdata.io’s website, and interested parties may use the online form provided here to schedule a 15-minute call with Danny Lieberman, Founder and CEO of Flaskdata.io. Social media users may also follow the company via the handle @flaskdata on Twitter to stay abreast of their most recent developments and announcements.